Azitra reports Phase 1b safety data for ATR12-351 in Netherton syndrome; no severe adverse events, 50% enrolled

Azitra, Inc.

No severe or serious adverse events in ongoing Phase 1b trial of ATR12-351; application site reactions transient, self-resolving, observed bilaterally.
Trial 50% enrolled; six patients dosed with ATR12-351 (engineered S. epidermidis strain delivering LEKTI protein).
Drug candidate generally safe and well-tolerated with occasional mild to moderate local symptoms (itch, redness, burning).
Azitra presenting at 2025 BIO International Convention on June 17, 2025 (12:00PM ET in Boston).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.